Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI:10.1080/14796678.2024.2343550

Juan José Gómez Doblas, Xavier García-Moll, Ramón Bover Freire, Carlos González Juanatey, Miren Morillas, Alfonso Valle Muñoz, Carlos Escobar

{"title":"Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting.","authors":"Juan José Gómez Doblas, Xavier García-Moll, Ramón Bover Freire, Carlos González Juanatey, Miren Morillas, Alfonso Valle Muñoz, Carlos Escobar","doi":"10.1080/14796678.2024.2343550","DOIUrl":null,"url":null,"abstract":"Background: Management of oral anticoagulation (OAC) can be challenging, such as in complex cases of nonvalvular atrial fibrillation (NVAF).Materials & methods: A Delphi study comprising two rounds was used for gathering expert opinion through an online questionnaire (83 items grouped in 8 dimensions) on OAC management in specific clinical settings.Results: Consensus was reached for 79 items (95%) in round 1. Experts recommended direct-acting oral anticoagulants (DOACs) for pericardioversion, uninterrupted OAC for catheter ablation, and dual therapy with a DOAC and clopidogrel after percutaneous coronary intervention. They also recommended restarting OAC with a DOAC after an intracranial haemorrhage.Conclusion: The expert-based recommendations obtained may contribute to standardizing and guiding the management of OAC in complex clinical situations in cardiology.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"695-708"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552477/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2343550","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Management of oral anticoagulation (OAC) can be challenging, such as in complex cases of nonvalvular atrial fibrillation (NVAF).Materials & methods: A Delphi study comprising two rounds was used for gathering expert opinion through an online questionnaire (83 items grouped in 8 dimensions) on OAC management in specific clinical settings.Results: Consensus was reached for 79 items (95%) in round 1. Experts recommended direct-acting oral anticoagulants (DOACs) for pericardioversion, uninterrupted OAC for catheter ablation, and dual therapy with a DOAC and clopidogrel after percutaneous coronary intervention. They also recommended restarting OAC with a DOAC after an intracranial haemorrhage.Conclusion: The expert-based recommendations obtained may contribute to standardizing and guiding the management of OAC in complex clinical situations in cardiology.

查看原文本刊更多论文

关于心脏病学特殊临床情况下口服抗凝管理的德尔菲共识。

背景：口服抗凝药（OAC）的管理可能具有挑战性，例如在非瓣膜性心房颤动（NVAF）的复杂病例中：通过在线问卷调查（83 个项目，分为 8 个维度）收集专家对特定临床环境下 OAC 管理的意见：专家建议心包翻转使用直接作用口服抗凝药（DOAC），导管消融使用不间断 OAC，经皮冠状动脉介入治疗后使用 DOAC 和氯吡格雷双重疗法。他们还建议在颅内出血后使用 DOAC 重启 OAC：以专家为基础的建议有助于规范和指导心脏病学复杂临床情况下的 OAC 管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.